3
Hours of Effort
to create the study budget and scenarios in Clinical Maestro™
4
Scenarios Built
Two (Original+Revised) reverse-engineering the provided assumptions, and two (Original+Revised) using the Clinical Maestro™ calculated assumptions.
-1.9%
Variance
between Awarded CRO budget and Clinical Maestro™ calculated budget in Original scenario.
+6.6%
Variance
between Awarded CRO budget and Clinical Maestro™ calculated budget in Revised scenario

In this case study
Strengthen your processes and increase data-driven decision-making for faster study start-ups.
Strengthen your processes and increase data-driven decision-making for faster study start-ups.
In an email table, the Sponsor provided key assumptions from a 2017 study for both the original scenario and a revised scenario. No protocol or study design was provided. The study was modeled as medium complexity using Clinical Maestrom's PORTFOLIO application for planning and budgeting. The results of the exercise were then presented to the Sponsor and the awarded CRO budget was revealed and compared.
Study description
- Phase 1
- Therapy Area: Oncology
- Indication: Biliary and Gallbladder Cancers
- USA, Thailand, S. Korea
Original & [Revised] Assumptions
- 41 [56] Sites
- 234 [297] Patients Screened
- 70 [89] Patients Enrolled
- 70 [89] Patients Completed
- 4 [1] Cohorts
- 266 [553] Total IMVs
- 14,000 [17,800] total eCRF pages
Results
With limited context provided by the Sponsor (no protocol, bid grid, tasks and responsibilities), the study budget built for the Original scenario using Clinical Maestro™™ was calculated to be $5,984,246 in direct fees. This presents a -1.9% variance from the awarded CRO budget ($6.1M).
The study budget built for the Revised scenario using Clinical Maestro™™ was calculated to be $9,709,488 in direct fees. This presents a +6.6% variance from the awarded CRO budget ($9.05M).
Variances are due to multiple factors including actual services outsourced, protocol-related assumptions, CRO expertise and operating model versus Clinical Maestro™™ "market" assumptions.
Conclusions
Clinical Maestro™™'s PORTFOLIO budget simulation tool predicted the study cost with near 99% accuracy in the Original study scenario and near 94% accuracy in the Revised study scenario.
Clinical Maestro™™ is an effective means to reliably predict study cost and evaluate the impact various operational scenarios may have on timelines and budget. Most importantly, it can be used during bid negotiations with Providers to uncover assumptions and guide questioning, helping Sponsors to better understand what they are paying for: rates, effort and services.
ClinicalMaestro™™ standardizes cost drivers and bid grids across the industry to simplify apple-to- apple comparisons on assumptions and task effort, strengthening Sponsor confidence on the fair market value for outsourced services.
In this case study
Strengthen your processes and increase data-driven decision-making for faster study start-ups.
RESOURCES
Explore Expert Insights and Resources for Clinical Excellence

Webinars
Technology for Fast, Accurate Planning and Budgeting
Leading biopharmaceutical sponsors trust PORTFOLIO for pipeline planning and budgeting with superior results and reported more than 10x Return on Investment.

Blogs
Driving Customer Success Through Governance: Transforming Pharma Vendor Management with AI Innovation
Effective vendor governance is essential to ensure operational success, cost efficiency, and regulatory compliance.

Case Studies
Streamlining Vendor Management: How a Leading Biopharma Company Found Success
DEMO
Request a demo
Discover how Strategikon’s advanced solutions can streamline your clinical trial operations. Request a personalized demo to explore how our tools transform budgeting, vendor management, and outsourcing efficiency for pharma and biotech.